Reducing Post-Operative Opioid Prescribing in Southeastern North Carolina
Building an Implementation Science Network to Reduce Post-Operative Opioid Prescribing in Southeastern North Carolina
The goal of this stepped-wedge cluster randomized trial is to evaluate whether an opioid stewardship intervention improves post-operative opioid prescribing practices. Participants will include surgeon champions and identified change team members (e.g., pharmacists, hospitalists, nurses, advanced practice providers, anesthesiologists, etc.) and patient representatives at designated hospital sites in North Carolina.
The main questions it aims to answer are:
I. Does the intervention reduce postoperative opioid prescribing behavior at the surgeon and hospital level? II. Is the intervention acceptable, feasible, and effective for implementation among participating hospitals?
Researchers will compare opioid prescribing and implementation outcomes across sites before and after implementation using a stepped-wedge cluster randomized design, in which sites are randomly assigned to different intervention start times.
Participants will attend educational sessions delivered, introduce the Standard Opioid Prescribing (SOPS) Toolkit into their clinical practice, review benchmarked, deidentified opioid prescribing performance reports that use administrative claims data (secondary data source, data not collected or shared between hospitals), and complete surveys assessing intervention acceptability, feasibility, and effectiveness. Preliminary effectiveness will be assessed through reduction of opioid prescriptions using administrative claims data.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
A stepped-wedge cluster randomized trial will be conducted across participating hospital sites in Southeastern North Carolina. Sites will transition sequentially from the control condition to the intervention condition based on randomization, until all clusters have completed the opioid stewardship intervention over a 10-week period.
During the control phase, opioid prescribing will continue according to existing practices. During the intervention phase, sites will implement a multi-component site-specific opioid stewardship intervention. The intervention includes dissemination of the Standard Opioid Prescribing (SOPS) Toolkit, quality improvement (QI) educational sessions, and benchmarked opioid prescribing performance reports generated from administrative claims data. These reports provide deidentified surgeon- and site-level prescribing summaries so that sites are able to see their current opioid prescribing levels.
The primary outcomes are the acceptability, feasibility, and effectiveness of the intervention assessed during and after implementation as determined from semi-structured interviews and surveys. Secondary outcomes include additional provider and patient opioid prescribing outcomes related to post-operative opioid fills by patients. This information will be obtained from administrative claims data. No patient information will be collected and no patient will be enrolled int eh study. These measures evaluate whether tailoring the opioid stewardship intervention to each hospital improves routine clinical practice and provider opioid prescribing.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jessica Schumacher, PhD
- Numéro de téléphone: (919) 966-4320
- E-mail: Jessica_Schumacher@med.unc.edu
Sauvegarde des contacts de l'étude
- Nom: Meaghan Hazelet
- E-mail: meaghan.hazelet@med.unc.edu
Lieux d'étude
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- University of North Carolina at Chapel Hill
-
Contact:
- Jessica Schumacher, PhD
- Numéro de téléphone: 919-966-4320
- E-mail: Jessica_Schumacher@med.unc.edu
-
Chercheur principal:
- Jessica Schumacher, PhD
-
Wilmington, North Carolina, États-Unis, 28401
- Novant Health New Hanover Regional Medical Center
-
Contact:
- William Hope, MD
- E-mail: william.hope@novanthealth.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Surgeon champions and identified change team members must be currently practicing at one of the sites participating in this study.
Patient representatives must be:
Proficient in the English language Prescribed opioids following a qualifying general surgery procedure (inpatient or outpatient laparoscopic appendectomy, inguinal/femoral hernia repair, umbilical hernia, bariatric/weight loss surgery, mastectomy, laparoscopic cholecystectomy, laparoscopic colectomy, lipoma/soft tissue tumor excision, and anal/rectal procedures).
No patients will be enrolled for this trial. However, claims data will be used to assess the claims based outcome measure (opioid prescribing).
Inclusion criteria for the claims analysis includes:
Patients greater than or equal to 18 at the time of a qualifying general surgery procedure either inpatient or outpatient (laparoscopic appendectomy; umbilical/ventral/inguinal/femoral hernia repair; bariatric/weight loss surgery; mastectomy; laparoscopic cholecystectomy; laparoscopic colectomy; lipoma/soft tissue tumor excision; anal/rectal procedures) based on procedure codes Patients must have continuous insurance coverage (including prescription drug coverage), 6 months before to 60 days post discharge to assess comorbidities and prescription drug fills.
Exclusion Criteria:
Patients with an opioid fill 6 months before the procedure. Patients who undergo a significant operation during the stay associated with their index procedure that would require additional pain management.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Usual Care (Control Period)
During the control phase of the stepped wedge cluster randomized trial, participating hospitals continue opioid prescribing according to existing local practices.
Clinicians do not receive any components of the opioid stewardship intervention during this period.
Each hospital contributes data to this arm prior to crossing over to the intervention phase based on randomized timing.
|
Existing opioid prescribing practices and guidelines at each participating hospital site, with no additional educational, benchmarking, or quality improvement activities.
|
|
Expérimental: Opioid Stewardship Intervention (Intervention Period)
During the intervention phase, hospitals implement a multi component opioid stewardship intervention after crossing over from the control condition according to randomized start time.
Clinician participants at each site engage in the intervention for approximately 10 weeks.
All hospitals eventually receive the intervention as part of the stepped wedge design.
|
A multi component intervention consisting of dissemination of the Standard Opioid Prescribing (SOPS) Toolkit, quality improvement educational sessions for clinicians, and benchmarked opioid prescribing performance reports generated from administrative claims data.
Reports provide deidentified surgeon and site level summaries of opioid prescribing patterns.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Acceptability of the Intervention Assessed by Semi-Structured Interviews (Change Team Members)
Délai: From enrollment through 6 months after completion of the 10-week intervention period
|
Acceptability will be assessed qualitatively using themes derived from semi-structured interviews conducted with change team members.
Interviews will explore perceptions of the intervention and its fit within the hospital context.
Themes identified after the 10-week implementation period will be compared with themes identified prior to implementation.
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
Proportion of training and learning sessions attended (Feasibility Measure 1)
Délai: From enrollment through 6 months after completion of the 10-week intervention period
|
Proportion of training and learning sessions attended by change team members
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
percentage of change team member providers that completed pre- and post- assessments (Feasibility Measure 2)
Délai: From enrollment through 6 months after completion of the 10-week intervention period
|
percentage of change team member providers that completed pre- and post- assessments
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
change team's ability to start the trial as randomized (Feasibility Measure 3)
Délai: From enrollment through 6 months after completion of the 10-week intervention period
|
change team's ability to start the trial as randomized (yes/no)
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
proportion of intervention components implemented (Feasibility Measure 4)
Délai: From enrollment through 6 months after completion of the 10-week intervention period
|
proportion of intervention components implemented using themes gathered from semi-structured interviews (intervention fidelity)
|
From enrollment through 6 months after completion of the 10-week intervention period
|
|
Change in Organizational Readiness to Change (ORIC) Measure (Effectiveness Measure 1- survey)
Délai: From enrollment through 6 months after completion of the 10-week intervention period)
|
Change in ORIC score from pre- to post intervention.
Change team members will complete the survey before the intervention start phase and after intervention completion.
|
From enrollment through 6 months after completion of the 10-week intervention period)
|
|
Audit and feedback effectiveness as assessed by learning sessions and semi structured interviews (Effectiveness Measure 2)
Délai: Intervention Period
|
Audit and feedback effectiveness is defined as the extent change team members feel ownership and agreement, can make sense of the information provided, are motivated by the social influence that reviewing their performance shows (e.g., comparing their performance to other hospitals), and accept accountability for the proposed changes.
|
Intervention Period
|
|
Change in Milligram equivalents (MME) of the first post-operative fill pre- and post-intervention using administrative claims data (Effectiveness Measure 3).
Délai: Comparing pre (6 months before enrollment) and 6 month period starting at the end of the 10-week intervention period.
|
Change in Milligram equivalents (MME) of the first opioid prescription filled (outpatient) by patients -3 days before admission for their qualifying procedure through 7 days post-discharge during the pre- and post-intervention time periods.
|
Comparing pre (6 months before enrollment) and 6 month period starting at the end of the 10-week intervention period.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Second opioid fill within 60-days of discharge (yes/no) using administative claims data
Délai: From enrollment through 6 months after completion of the 10-week intervention period
|
For patients with one or more post-operative opioids filled, the proportion that filled a second prescription within 60 days of discharge from the qualifying procedure
|
From enrollment through 6 months after completion of the 10-week intervention period
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Jessica Schumacher, PhD, University of North Carolina, Chapel Hill
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 25-1636
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .